Drug General Information
Drug ID	D04SLF
Former ID	DCL000497
Drug Name	Bevacizumab + Trastuzumab
Drug Type	Antibody
Indication	Metastatic breast cancer [ICD10:C50]		Phase 3	[532301]
	Breast cancer [ICD9: 174, 175; ICD10:C50]		Phase 2	[554002]
Company	Roche
Structure		Download 2D MOL 3D MOL
Formula	C24H40O3
PubChem Compound ID	9903
Target and Pathway
Target(s)	Vascular endothelial growth factor	Target Info	Inhibitor	[551607]
	Receptor protein-tyrosine kinase erbB-2	Target Info		[551607]
KEGG Pathway	ErbB signaling pathway
	Calcium signaling pathway
	HIF-1 signaling pathway
	Focal adhesion
	Adherens junction
	Pathways in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Pancreatic cancer
	Endometrial cancer
	Prostate cancer
	Bladder cancer
	Non-small cell lung cancer
	Central carbon metabolism in cancer
NetPath Pathway	TCR Signaling Pathway
PANTHER Pathway	Cadherin signaling pathway
	EGF receptor signaling pathway
Pathway Interaction Database	ErbB4 signaling events
	ErbB2/ErbB3 signaling events
	ErbB receptor signaling network
	a6b1 and a6b4 Integrin signaling
	Validated targets of C-MYC transcriptional repression
PathWhiz Pathway	Phosphatidylinositol Phosphate Metabolism
Reactome	SHC1 events in ERBB2 signaling
	PLCG1 events in ERBB2 signaling
	PIP3 activates AKT signaling
	GRB2 events in ERBB2 signaling
	PI3K events in ERBB2 signaling
	Constitutive Signaling by Aberrant PI3K in Cancer
	Sema4D induced cell migration and growth-cone collapse
	RAF/MAP kinase cascade
WikiPathways	DNA Damage Response (only ATM dependent)
	ErbB Signaling Pathway
	EGF/EGFR Signaling Pathway
	Focal Adhesion
	Extracellular vesicle-mediated signaling in recipient cells
	Bladder Cancer
	Signaling by ERBB2
	Integrated Pancreatic Cancer Pathway
	Signaling Pathways in Glioblastoma
	Leptin signaling pathway
	miR-targeted genes in muscle cell - TarBase
	Semaphorin interactions
References
Ref 532301	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25.
Ref 554002	ClinicalTrials.gov (NCT00365365) Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
Ref 551607	Clinical pipeline report, company report or official report of Roche (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.